Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnWeb3SquareMore
Trade
Spot
Buy and sell crypto with ease
Margin
Amplify your capital and maximize fund efficiency
Onchain
Going Onchain, without going Onchain!
Convert & block trade
Convert crypto with one click and zero fees
Explore
Launchhub
Gain the edge early and start winning
Copy
Copy elite trader with one click
Bots
Simple, fast, and reliable AI trading bot
Trade
USDT-M Futures
Futures settled in USDT
USDC-M Futures
Futures settled in USDC
Coin-M Futures
Futures settled in cryptocurrencies
Explore
Futures guide
A beginner-to-advanced journey in futures trading
Futures promotions
Generous rewards await
Overview
A variety of products to grow your assets
Simple Earn
Deposit and withdraw anytime to earn flexible returns with zero risk
On-chain Earn
Earn profits daily without risking principal
Structured Earn
Robust financial innovation to navigate market swings
VIP and Wealth Management
Premium services for smart wealth management
Loans
Flexible borrowing with high fund security
Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety

Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety

Bitget-RWA2025/10/24 12:32
By:Bitget-RWA

- Inhibrx Biosciences’ ozekibart showed 52% reduced disease progression risk in chondrosarcoma, driving a 70% post-market stock surge. - Combination trials in colorectal and Ewing sarcoma showed 23%–64% response rates, suggesting broader oncology potential. - Hepatotoxicity concerns led to monitoring strategies, reducing adverse events to 11.8% in ozekibart group. - Company plans 2026 BLA submission; stock surged 63% pre-market after prior 10% decline.

Shares of Inhibrx Biosciences (NASDAQ:INBX) soared by more than 70% in after-hours trading on October 23, 2025, after the company announced encouraging Phase 2 trial data for its investigational cancer therapy ozekibart (INBRX-109) in chondrosarcoma, a rare and aggressive bone malignancy that currently lacks approved systemic treatments, as reported by an

. The ChonDRAgon clinical trial, which compared ozekibart as a standalone treatment to placebo, achieved its main goal by showing a statistically significant 52% decrease in the risk of disease progression or death relative to the control group. Patients administered ozekibart experienced a median progression-free survival (PFS) of 5.52 months, more than twice the 2.66 months seen in those receiving placebo. Additionally, the drug achieved a disease control rate of 54% compared to 27.5% for placebo, with consistent positive outcomes across all predefined subgroups, according to .

Ozekibart’s safety profile was generally acceptable, though liver toxicity was identified as a significant issue. Early in the study, a fatal liver-related incident led to the adoption of risk mitigation strategies, including excluding patients with advanced liver dysfunction and closely monitoring liver function during the initial treatment cycles. These interventions reduced the rate of treatment-related liver side effects to 11.8% in the ozekibart group versus 4.5% in the placebo group, with most cases being mild or moderate in severity, as detailed in

.

Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety image 0

In addition to chondrosarcoma,

shared encouraging interim results from expansion cohorts evaluating ozekibart in combination regimens for colorectal cancer and Ewing sarcoma. Among heavily pretreated colorectal cancer patients, the combination of ozekibart with FOLFIRI chemotherapy resulted in a 23% overall response rate and a 92% disease control rate. For Ewing sarcoma, pairing ozekibart with irinotecan and temozolomide yielded a 64% overall response rate and a 92% disease control rate, as reported by Investing.com. These outcomes indicate that the therapy may have broader potential in oncology.

The company intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration in the second quarter of 2026, according to Investing.com. Comprehensive data from the ChonDRAgon study will be presented at the Connective Tissue Oncology Society Annual Meeting on November 14, 2025, as noted by Tokenist.

The market responded strongly to the announcement, with

shares climbing from $28.36 on October 23 to $46.30 in pre-market trading the next day—a 63.26% increase, according to Tokenist. This jump followed a 10% drop in the previous session, highlighting the volatility typical of biotech equities. Trading volume surged to 1.15 million shares, far above the average of 151,435, per Tokenist. Retail investors on platforms such as Stocktwits became "extremely bullish," with message activity rising by 985% in 24 hours, as tracked by .

Financially, Inhibrx has a market capitalization near $457 million and maintains strong liquidity, with a current ratio close to 5, according to

. However, the company posted a net loss of $28.65 million in the latest quarter, mainly due to substantial research and development spending, as reported by . Despite these losses, analysts see ozekibart as a potential revenue driver if it gains regulatory approval.

INBX shares have climbed 140% year-to-date, reflecting strong investor confidence, though some warn that commercial success will depend on overcoming regulatory challenges and proving long-term effectiveness. With no approved therapies for chondrosarcoma, ozekibart’s potential to be first to market has drawn parallels to other breakthrough drugs in specialized oncology fields, according to Stocktwits.

0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!

You may also like

Bitcoin News Update: Crypto Recovery After Crash: Risky Presale Opportunities or Institutional Investment?

- Post-crash crypto rebound sees investors favoring projects with strong fundamentals and high-growth presales like BullZilla, Blazpay, and DeepSnitch AI. - Ethereum rebounds to $3,941.73 amid institutional confidence in Layer-2 upgrades and DeFi dominance, while BNB surges 6% post-CZ pardon. - High-risk presales offer asymmetric returns: $100 in DeepSnitch AI could yield $10,000 if token hits $2 post-launch. - Bitcoin Hyper aims to enhance Bitcoin's scalability via Solana integration, raising $24.4M for Q

Bitget-RWA2025/10/25 07:08
Bitcoin News Update: Crypto Recovery After Crash: Risky Presale Opportunities or Institutional Investment?

XRP News Today: XRP Whales Sell 70M, Retail Investors Drive Price Up by Absorbing Supply

- XRP whales sold 70M tokens in two weeks, yet price rose to $2.55 amid retail/institutional buying. - Whale holdings increased (12.65% at 1M-10M range) while futures funding rates turned positive, signaling bullish sentiment. - Technical indicators show bullish reversal patterns, but price remains below 50-day SMA and faces $2.60 resistance. - Regulatory delays (SEC ETF decisions) and macro risks persist, though institutional demand stabilizes via Evernorth's $1B Nasdaq listing plan.

Bitget-RWA2025/10/25 06:50

Solana Latest Updates: Optimism for Solana ETF Faces Challenges Amid Waning Momentum as $200 Approaches

- Solana's price hovers near $183 amid speculation about potential U.S. spot-SOL ETF approval following Hong Kong's regulatory green light. - Technical analysis shows mixed signals: a $200 breakout could drive momentum toward $230–$300, while support below $175 risks a pullback to $160–$165. - Despite 85% bullish community sentiment and institutional adoption potential, declining on-chain activity and regulatory uncertainties cloud near-term outlook. - Upcoming Solana Breakpoint conference in December will

Bitget-RWA2025/10/25 06:50
Solana Latest Updates: Optimism for Solana ETF Faces Challenges Amid Waning Momentum as $200 Approaches